β2 microglobulin, which has recently been demonstrated to distinguish patients with HAM/TSP from HTLV-1 asymptomatic carriers with a relationship between concentration and degree of motor disability [27] should therefore be tested in larger clinical trials as a peripheral blood surrogate marker of HAM/TSP response to therapy. The gene discussed is HLA-G; the disease is tropical spastic paraparesis.